Cypress Bioscience, Inc.

Imre Corporation

Harry W Snyder

Frank R Jones

Joseph P Balint

Sharon Cochran

Immune thrombocytopenic purpura is treated by removal of IgG and circulating immune complexes from the patient's blood. Removal is accomplished by exposing the blood or blood plasma to an immunoadsorbent capable of removing IgG and its complexes. The immunoadsorbent comprises a suitable solid phase coupled to a receptor capable of binding IgG and its complexes, such as protein A. The IgG and its complexes are then removed by the extracorporeal exposure of the patient's blood to the immunoadsorbent, either in a continuous or discontinuous process. In the continuous process, the blood is removed in a steady flow from the patient, separated into its plasma and cellular components, the plasma treated, and the combined cellular components and treated plasma reinfused to the patient. In the discontinuous method, a small volume of blood is removed from the patient, the entire volume separated into plasma and cellular components, the plasma treated, and the entire volume of treated plasma returned to the patient, usually after the cellular components have been returned.

Method for treating patients suffering from immune thrombocytopenic

Antibody is removed from the blood of patients who are being treated or diagnosed with exogenous macromolecules, such as immunotoxins. As the immunotoxins are foreign antigens, the patient will develop an immune response. The antibodies produced by the immune response upon subsequent immunization with the immunotoxins will interfere with the desired function of the immunotoxins by preventing them from binding with their specific target site. By extracorporeally removing the antibodies, the activity of the immunotoxins can be enhanced.

Growing community of inventors

Edmonds, WA, United States of America

Harry W Snyder